Convatec Group PLC (LON:CTEC – Get Free Report) insider Jens Viebke acquired 24,400 shares of Convatec Group stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average price of GBX 230 per share, with a total value of £56,120.
Convatec Group Price Performance
Shares of LON CTEC opened at GBX 238.40 on Friday. The stock has a market capitalization of £4.57 billion, a price-to-earnings ratio of 38.45, a PEG ratio of 0.93 and a beta of 0.77. The business has a 50-day moving average of GBX 223.66 and a 200-day moving average of GBX 217.88. The company has a debt-to-equity ratio of 121.83, a current ratio of 1.93 and a quick ratio of 0.96. Convatec Group PLC has a fifty-two week low of GBX 193 and a fifty-two week high of GBX 259.30.
Wall Street Analyst Weigh In
A number of research firms have weighed in on CTEC. Jefferies Financial Group restated a “buy” rating and issued a GBX 300 price target on shares of Convatec Group in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 315 price objective on shares of Convatec Group in a research note on Wednesday, August 5th. Royal Bank Of Canada reissued an “outperform” rating and issued a GBX 315 price objective on shares of Convatec Group in a report on Monday, August 3rd. Peel Hunt reissued an “add” rating and issued a GBX 270 target price on shares of Convatec Group in a research note on Tuesday, August 4th. Finally, Berenberg Bank decreased their target price on shares of Convatec Group from GBX 340 to GBX 335 and set a “buy” rating for the company in a research note on Friday, September 11th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of GBX 305.44.
View Our Latest Stock Analysis on Convatec Group
About Convatec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Recommended Stories
- Five stocks we like better than Convatec Group
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Convatec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Convatec Group and related companies with MarketBeat.com's FREE daily email newsletter.
